John McCall

Co-Founder, Chairman of the Board and Vice President of Chemistry at ReveraGen BioPharma, which focuses on developing therapeutics for Duchenne muscular dystrophy. Dr. McCall’s expertise includes medicinal biochemistry, steroidal chemistry, risk minimization and strategic planning.

Dr. McCall’s distinguished career includes senior roles with Upjohn, Pharmacia and Pfizer. He also has extensive consulting experience, advising National Institutes of Health (“NIH”), academic, and pharmaceutical partners in the translational drug discovery and development areas.

Dr. McCall’s Board and Scientific Advisory Board positions include UCB, CeeTox, Synergenics, Psychogenics, Avaant, Deciphera, Lycera, Michigan High Throughput Screening Center, Verseon, CINRG, Reaction Biology, Scripps, AdmetRx, and PharmOptima.

He holds 54 U.S. patents and has more than 60 refereed publications.